Epstein-Barr Virus LMP2A Imposes Sensitivity to Apoptosis

Overview

Journal J Gen Virol

Specialty Microbiology

Date 2010 May 21

PMID 20484564

Citations 15

Authors

Michelle Swanson-Mungerson

Rebecca Bultema

Richard Longnecker

Affiliations

Soon will be listed here.

Abstract

In cell lines, the Epstein-Barr virus (EBV)-encoded protein latent membrane protein 2A (LMP2A) protects B-cells from apoptosis by blocking B-cell receptor (BCR) signalling. However, EBV-infected B-cells in vivo are extremely different from cell lines. This study used a murine transgenic model in which B-cells express LMP2A and a BCR specific for hen egg lysozyme to determine whether LMP2A protects resting and antigen-activated B-cells from apoptosis. LMP2A allows BCR signal transduction and induces constitutive activation of NF-kappaB to increase Bcl-2 levels that afford LMP2A-mediated protection from apoptosis in the absence or presence of antigen. In contrast, low levels of NF-kappaB inhibitor only affected Bcl-2 and Bcl-xL levels and increased apoptosis in LMP2A-negative B-cells after BCR cross-linking. These data suggest that LMP2A uniquely makes resting B-cells sensitive to NF-kappaB inhibition and apoptosis and suggest that NF-kappaB may be a novel target to eradicate latently EBV-infected B-cells.

Citing Articles

Viral Oncogenesis: Synergistic Role of Genome Integration and Persistence.

La Frazia S, Pauciullo S, Zulian V, Garbuglia A Viruses. 2025; 16(12.

PMID: 39772271 PMC: 11728759. DOI: 10.3390/v16121965.

The impact of Epstein-Barr virus latent membrane protein 2A on the production of B cell activating factor of the tumor necrosis factor family (BAFF), APRIL and their receptors.

Madayag K, Incrocci R, Swanson-Mungerson M Immun Inflamm Dis. 2022; 10(11):e729.

PMID: 36301035 PMC: 9597489. DOI: 10.1002/iid3.729.

The interplay between Epstein-Bar virus (EBV) with the p53 and its homologs during EBV associated malignancies.

Chatterjee K, Das P, Roy Chattopadhyay N, Mal S, Choudhuri T Heliyon. 2019; 5(11):e02624.

PMID: 31840114 PMC: 6893087. DOI: 10.1016/j.heliyon.2019.e02624.

The Role of miRNAs in Virus-Mediated Oncogenesis.

Vojtechova Z, Tachezy R Int J Mol Sci. 2018; 19(4).

PMID: 29673190 PMC: 5979478. DOI: 10.3390/ijms19041217.

Identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-Hodgkin's lymphoma.

Xiao X, Li H, Jin H, Jin J, Yu M, Ma C Cell Death Dis. 2017; 8(9):e3050.

PMID: 28906487 PMC: 5636986. DOI: 10.1038/cddis.2017.442.

References

CALDWELL R, Wilson J, Anderson S, Longnecker R . Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity. 1998; 9(3):405-11. DOI: 10.1016/s1074-7613(00)80623-8. View

Portis T, Longnecker R . Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene. 2004; 23(53):8619-28. DOI: 10.1038/sj.onc.1207905. View

Kis L, Salamon D, Persson E, Nagy N, Scheeren F, Spits H . IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter. Proc Natl Acad Sci U S A. 2010; 107(2):872-7. PMC: 2818931. DOI: 10.1073/pnas.0912920107. View

Lung R, Tong J, Sung Y, Leung P, Ng D, Chau S . Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia. 2009; 11(11):1174-84. PMC: 2767219. DOI: 10.1593/neo.09888. View

Babcock G, Thorley-Lawson D . Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc Natl Acad Sci U S A. 2000; 97(22):12250-5. PMC: 17327. DOI: 10.1073/pnas.200366597. View

Hochberg D, Middeldorp J, Catalina M, Sullivan J, Luzuriaga K, Thorley-Lawson D . Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci U S A. 2003; 101(1):239-44. PMC: 314169. DOI: 10.1073/pnas.2237267100. View

Tsai S, Lin S, Chen P, Luo W, Yeh T, Wang H . EBV Zta protein induces the expression of interleukin-13, promoting the proliferation of EBV-infected B cells and lymphoblastoid cell lines. Blood. 2009; 114(1):109-18. PMC: 2710941. DOI: 10.1182/blood-2008-12-193375. View

Mancao C, Hammerschmidt W . Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood. 2007; 110(10):3715-21. PMC: 2077319. DOI: 10.1182/blood-2007-05-090142. View

Dawson C, George J, Blake S, Longnecker R, Young L . The Epstein-Barr virus encoded latent membrane protein 2A augments signaling from latent membrane protein 1. Virology. 2001; 289(2):192-207. DOI: 10.1006/viro.2001.1142. View

10.

Fukuda M, Longnecker R . Epstein-Barr virus (EBV) latent membrane protein 2A regulates B-cell receptor-induced apoptosis and EBV reactivation through tyrosine phosphorylation. J Virol. 2005; 79(13):8655-60. PMC: 1143726. DOI: 10.1128/JVI.79.13.8655-8660.2005. View

11.

Grossmann M, OReilly L, Gugasyan R, Strasser A, Adams J, Gerondakis S . The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression. EMBO J. 2000; 19(23):6351-60. PMC: 305873. DOI: 10.1093/emboj/19.23.6351. View

12.

Kis L, Takahara M, Nagy N, Klein G, Klein E . IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines. Blood. 2005; 107(7):2928-35. DOI: 10.1182/blood-2005-06-2569. View

13.

CALDWELL R, Brown R, Longnecker R . Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J Virol. 2000; 74(3):1101-13. PMC: 111444. DOI: 10.1128/jvi.74.3.1101-1113.2000. View

14.

Anderson L, Longnecker R . An auto-regulatory loop for EBV LMP2A involves activation of Notch. Virology. 2007; 371(2):257-66. PMC: 2288488. DOI: 10.1016/j.virol.2007.10.009. View

15.

Weil R, Israel A . T-cell-receptor- and B-cell-receptor-mediated activation of NF-kappaB in lymphocytes. Curr Opin Immunol. 2004; 16(3):374-81. DOI: 10.1016/j.coi.2004.03.003. View

16.

Babcock G, Decker L, Volk M, Thorley-Lawson D . EBV persistence in memory B cells in vivo. Immunity. 1998; 9(3):395-404. DOI: 10.1016/s1074-7613(00)80622-6. View

17.

Schulze-Luehrmann J, Ghosh S . Antigen-receptor signaling to nuclear factor kappa B. Immunity. 2006; 25(5):701-15. DOI: 10.1016/j.immuni.2006.10.010. View

18.

Grillot D, Merino R, PENA J, Fanslow W, Finkelman F, Thompson C . bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice. J Exp Med. 1996; 183(2):381-91. PMC: 2192442. DOI: 10.1084/jem.183.2.381. View

19.

Babcock G, Hochberg D . The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity. 2000; 13(4):497-506. DOI: 10.1016/s1074-7613(00)00049-2. View

20.

Swanson-Mungerson M, Caldwell R, Bultema R, Longnecker R . Epstein-Barr virus LMP2A alters in vivo and in vitro models of B-cell anergy, but not deletion, in response to autoantigen. J Virol. 2005; 79(12):7355-62. PMC: 1143642. DOI: 10.1128/JVI.79.12.7355-7362.2005. View